Crescent Biopharma Inc (NASDAQ:CBIO)’s traded shares stood at 0.17 million during the last session, with the company’s beta value hitting 1.52. At the close of trading, the stock’s price was $15.89, to imply an increase of 2.22% or $0.34 in intraday trading. The CBIO share’s 52-week high remains $63.00, putting it -296.48% down since that peak but still an impressive 30.4% since price per share fell to its 52-week low of $11.06. The company has a valuation of $10.25M, with an average of 76730.0 shares in intraday trading volume over the past 10 days and average of 30.26K shares over the past 3 months.
Analysts have given a consensus recommendation of Hold for Crescent Biopharma Inc (CBIO), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give CBIO a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 0 recommend it as a Buy.
Crescent Biopharma Inc (NASDAQ:CBIO) trade information
After registering a 2.22% upside in the last session, Crescent Biopharma Inc (CBIO) has traded red over the past five days. The 5-day price performance for the stock is -5.98%, and -23.97% over 30 days. With these gigs, the year-to-date price performance is -46.34%.
Crescent Biopharma Inc (CBIO) estimates and forecasts
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 15.18% for the past 5-year period. While 2025 is set for a 92.98% return in earnings, projections for the next 5 years are at 61.53% annually.
CBIO Dividends
Crescent Biopharma Inc has its next earnings report out on 2023-Oct-26. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Crescent Biopharma Inc (NASDAQ:CBIO)’s Major holders
Crescent Biopharma Inc insiders hold 0.16% of total outstanding shares, with institutional holders owning 12.09% of the shares at 12.10% float percentage. In total, 12.09% institutions holds shares in the company.
We also have VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Crescent Biopharma Inc (CBIO) shares. Going by data provided on Mar 31, 2025, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund holds roughly 19.25 shares. This is just over 0.14% of the total shares, with a market valuation of $0.31 million. Data from the same date shows that the other fund manager holds a little less at 7.31, or 0.05% of the shares, all valued at about 0.12 million.
